INS and Hypoglycemia: Given its greater affordability, patients who are well controlled on NPH may be able to continue on this therapy, since reductions in severe hypoglycemia with newer basal insulin analogs compared with NPH seen in some clinical trials may not be evident in clinical practice [23].